Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer

PURPOSE: AZD1775 (adavosertib) is an inhibitor of the Wee1 kinase. In this study, we built on our preclinical studies to evaluate the safety and efficacy of AZD1775 in combination with gemcitabine and radiation in patients with newly diagnosed locally advanced pancreatic cancer. PATIENTS AND METHODS...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Clin Oncol
Prif Awduron: Cuneo, Kyle C., Morgan, Meredith A., Sahai, Vaibhav, Schipper, Matthew J., Parsels, Leslie A., Parsels, Joshua D., Devasia, Theresa, Al-Hawaray, Mahmoud, Cho, Clifford S., Nathan, Hari, Maybaum, Jonathan, Zalupski, Mark M., Lawrence, Theodore S.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Clinical Oncology 2019
Pynciau:
ORIGINAL REPORTS
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7006846/
https://ncbi.nlm.nih.gov/pubmed/31398082
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.00730
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg